This company has been marked as potentially delisted and may not be actively trading. NASDAQ:HLVX HilleVax (HLVX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About HilleVax Stock (NASDAQ:HLVX) Get HilleVax alerts:Sign Up Key Stats Today's Range$2.09▼$2.0950-Day Range$2.06▼$2.1252-Week Range$1.77▼$2.17VolumeN/AAverage Volume532,880 shsMarket Capitalization$104.79 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview HilleVax, Inc. is a clinical-stage biotechnology company focused on the development of broadly protective vaccines against enteric pathogens. The company leverages a proprietary O-antigen platform to generate multivalent vaccine candidates designed to elicit immunity to multiple strains of enterotoxigenic Escherichia coli (ETEC), Shigella and Vibrio cholerae. HilleVax’s lead candidate, HIL-214, is currently advancing through Phase I clinical trials to assess safety and immunogenicity in adult populations. Founded as a spin-out from Hilleman Laboratories with support from philanthropic and industry partners, HilleVax has built a pipeline of product candidates aimed at addressing diseases that disproportionately impact low- and middle-income countries as well as travelers. In addition to HIL-214, the company is developing second-generation candidates for shigellosis and cholera, each leveraging the same O-antigen conjugation technology to streamline manufacturing and broaden strain coverage. Strategic collaborations and research partnerships underpin the company’s efforts to optimize vaccine formulations and accelerate global development. Headquartered in Cambridge, Massachusetts, HilleVax conducts research and development activities in the United States while engaging with international public health agencies, academic institutions and non-governmental organizations to support clinical trial execution and eventual vaccine deployment. Led by CEO William J. Harty, the management team brings extensive experience in vaccine development, regulatory affairs and global commercialization planning. As a publicly listed entity on NASDAQ under the symbol HLVX, HilleVax is positioning itself to address unmet medical needs in enteric disease prevention on a global scale.AI Generated. May Contain Errors. Read More Receive HLVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HilleVax and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HLVX Stock News HeadlinesHILLEVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVXAugust 19, 2025 | globenewswire.comHilleVax, Inc. Reports Q2 2025 Financial ResultsAugust 15, 2025 | tipranks.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.May 12 at 1:00 AM | InvestorPlace (Ad)HilleVax Announces Merger Agreement with XOMAAugust 14, 2025 | theglobeandmail.comShareholder Alert: The Ademi Firm Investigates Whether HilleVax, Inc. Is Obtaining a Fair Price for Its Public ShareholdersAugust 8, 2025 | businesswire.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of HilleVax, Inc. (NASDAQ: HLVX)August 7, 2025 | prnewswire.comHilleVax Reports Second Quarter 2025 Financial ResultsAugust 6, 2025 | globenewswire.comHILLEVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVXAugust 5, 2025 | businesswire.comSee More Headlines HLVX Stock Analysis - Frequently Asked Questions How were HilleVax's earnings last quarter? HilleVax, Inc. (NASDAQ:HLVX) issued its quarterly earnings results on Wednesday, August, 6th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. When did HilleVax IPO? HilleVax (HLVX) raised $200 million in an initial public offering (IPO) on Thursday, April 28th 2022. The company issued 11,765,000 shares at a price of $16.00-$18.00 per share. What other stocks do shareholders of HilleVax own? Based on aggregate information from My MarketBeat watchlists, some other companies that HilleVax investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META) and Home Depot (HD). Company Calendar Last Earnings8/06/2025Today5/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 HLVX's financial health is in the Green zone, according to TradeSmith. HLVX has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HLVX CIK1888012 Webwww.hillevax.com Phone617-213-5054FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$147.27 million Net MarginsN/A Pretax MarginN/A Return on Equity-34.29% Return on Assets-28.50% Debt Debt-to-Equity RatioN/A Current Ratio26.39 Quick Ratio26.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.10 per share Price / Book0.67Miscellaneous Outstanding Shares50,140,000Free Float37,656,000Market Cap$104.79 million OptionableNot Optionable Beta0.77 The 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:HLVX) was last updated on 5/12/2026 by MarketBeat.com Staff. From Our PartnersRead this or regret it foreverThree Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredMusk’s Next $4 Trillion Takeover Target – It’s Stranger than you ThinkTech analyst Ian King - who called an early Tesla trade that returned up to 1,000% in just over a year - says ...Banyan Hill Publishing | SponsoredGold Is About to Do Something It Hasn’t in 90 YearsThe U.S. Treasury still carries America's gold reserves at $42 per ounce — a price set generations ago. Buried...US Gold Bureau | SponsoredYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...Profits Run | SponsoredI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HilleVax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HilleVax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
